Market Research Reports

Insulin Market - Global And China Industry Analysis, Size, Share, Growth, And Forecast 2011 - 2018

105pages
Published Date: 2012-09-19
 

Description




This report is an effort to identify factors, which will be the driving force behind the insulin market and sub-markets in the next few years. The report provides extensive analysis of the insulin industry, current market trends, industry drivers and challenges for better understanding of the insulin industry structure. The report has segregated the insulin industry in terms of product type, purchase type, action, and geography. It also highlights price trends of all insulin product market segments. We have used a combination of primary and secondary research to arrive at the market estimates, market shares and trends. We have adopted bottom up model to derive market size of the global insulin industry and further validated numbers with the key market participants and C-level executives. 

This report highlights the insulin industry with the following points:
  • Definition, estimates & forecast of the insulin industry from 2007 to 2017
  • Analysis of product segments for the insulin market with historical data and forecast
  • Trends and forecast for global and China markets, based on segments of insulin products market
  • Market shares of major players and strategies followed by them for gaining competitive advantage
  • Profiles of major market participants for better understanding of their contributions

This research is specially designed to estimate and analyze the demand and performance of insulin products in a global scenario. The research provides in-depth analysis of insulin manufacturers, product sales, trend analysis by segments, and demand by geography. The report covers all the major product segments of the global insulin industry and provides historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the global insulin market as below:

INSULIN MARKET

BY ACTION
  • Short acting
  • Pre-mixes
  • Long acting
BY PRODUCT TYPE
  • Modern insulin
  • Human insulin
  • Animal insulin
BY PURCHASE TYPE
  • Dosage
  • Bulk 

In addition the report provides a cross-sectional analysis of all the above segments with respect to following geographical markets:

  • Global
  • China

The in-depth research and high level analysis will allow insulin product manufacturers, service providers, large retailers, pharmaceutical companies, and research and development agencies to make informed decisions about insulin manufacturing, marketing and growth strategies, and gaining competitive advantage.

For the research report, we conducted in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents the bulk of our research efforts, supplemented by extensive secondary research. We reviewed the key players’ product literature, annual reports, press releases and relevant documents for competitive analysis and market understanding. Secondary research also includes a search of recent trade journals, technical writing, internet sources, and statistical data from government websites, trade associations and agencies. This approach has proven to be the most reliable, effective and successful approach for obtaining precise market data, capturing industry participants’ insights, and recognizing business opportunities.

Reasons to Buy this Report
  • This research report will provide a forward perspective on market issues affecting market growth rate
  • It will help in understanding the competitive environment and make accurate and informed business decisions to withstand competition
  • The report will provide pin-point analysis of changing competition dynamics to keep one ahead of competitors
  • It will provide an in-depth analysis of key product segments and robust product segments
  • The research report provides a seven-year forecast on business projections and segmental behavior

Table of Contents




TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 SCOPE OF THE REPORT
1.3 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 GLOBAL INSULIN MARKET, 2011 - 2018
3.1 MARKET OVERVIEW
3.2 GLOBAL INSULIN MARKET SIZE REVENUE, 2011 - 2018 (USD MILLION)
3.3 GLOBAL INSULIN MARKET SIZE VOLUME, 2011 - 2018 (TMU)
3.4 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
3.5 GLOBAL INSULIN MARKET SHARE, 2011
3.6 MACROECONOMIC FACTORS
      3.6.1 GLOBAL POPULATION GROWTH, 2011 - 2018 (MILLION)
      3.6.2 GLOBAL DIABETES POPULATION GROWTH, 2011 – 2030 (27 – 79 YEARS)
      3.6.3 GLOBAL DIABETES PREVALANCE RATES BY AGE GROUP, 2011 – 2030
      3.6.4 GLOBAL GROSS DOMESTIC PRODUCT (GDP) PER CAPITA, 2011 - 2018 (USD)
3.7 INSULIN MARKET SEGMENTATION
3.8 PRICE TRENDS
      3.8.1 GLOBAL PRICE TRENDS
              3.8.1.1 PRICE TRENDS – BY ACTION
              3.8.1.2 PRICE TRENDS – BY TYPE
              3.8.1.3 PRICE TRENDS – BY PURCHASE TYPE

CHAPTER 4 CHINA INSULIN MARKET, 2011 - 2018
4.1 MARKET OVERVIEW
4.2 CHINA INSULIN MARKET SIZE REVENUE, 2011 - 2018 (USD MILLION)
4.3 CHINA INSULIN MARKET SIZE VOLUME, 2011 - 2018 (TMU)
4.4 DEMAND GROWTH TREND FOR INSULIN IN CHINA, 2011 - 2018 (%)
4.5 CHINESE INSULIN MARKET SHARE, 2011
4.6 MACROECONOMIC FACTORS
      4.6.1 POPULATION GROWTH OF CHINA, 2010 - 2018 (MILLION)
      4.6.2 CHINESE DIABETES POPULATION GROWTH, 2011 - 2030(27 – 79 YEARS)
      4.6.3 CHINA DIABETES PREVALANCE RATES BY AGE GROUP, 2011 – 2030
      4.6.4 GROSS DOMESTIC PRODUCT PER CAPITA OF CHINA, 2011 - 2018 (USD)
      4.6.5 PRICE TRENDS
              4.6.5.1 PRICE TRENDS – BY ACTION
              4.6.5.2 PRICE TRENDS – BY TYPE
              4.6.5.3 PRICE TRENDS – BY PURCHASE TYPE

CHAPTER 5 GLOBAL INSULIN MARKET REVENUE AND VOLUME – BY SEGMENT
5.1 GLOBAL SHORT ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.2 GLOBAL SHORT ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.3 GLOBAL PRE-MIXES INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.4 GLOBAL PRE-MIXES INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.5 GLOBAL LONG ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.6 GLOBAL LONG ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.7 GLOBAL HUMAN INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.8 GLOBAL HUMAN INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.9 GLOBAL MODERN INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.10 GLOBAL MODERN INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.11 GLOBAL ANIMAL INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.12 GLOBAL ANIMAL INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.13 GLOBAL DOSAGE PURCHASE INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.14 GLOBAL DOSAGE PURCHASE INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
5.15 GLOBAL BULK PURCHASE INSULIN MARKET REVENUE, 2011 – 2018 (USD)
5.16 GLOBAL BULK PURCHASE INSULIN MARKET VOLUME, 2011 - 2018 (TMU)

CHAPTER 6 CHINA INSULIN MARKET REVENUE AND VOLUME – BY SEGMENT
6.1 CHINA SHORT ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.2 CHINA SHORT ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.3 CHINA PRE-MIXES INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.4 CHINA PRE-MIXESINSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.5 CHINA LONG ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.6 CHINA LONG ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.7 CHINA HUMAN INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
6.8 CHINA HUMAN INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.9 CHINA MODERN INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.10 CHINA MODERN INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.11 CHINA ANIMAL INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.12 CHINA ANIMAL INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.13 CHINA DOSAGE PURCHASE INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.14 CHINA DOSAGE PURCHASE INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
6.15 CHINA BULK PURCHASE INSULIN MARKET REVENUE, 2011 – 2018 (USD)
6.16 CHINA BULK PURCHASE INSULIN MARKET VOLUME, 2011 - 2018 (TMU)

CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 COMPETITIVE STRATEGY BY KEY PLAYERS
7.2 CHINESE INSULIN MARKET SHARE BY KEY PLAYERS, 2009 – 2011

CHAPTER 8 COMPANY PROFILE
8.1 NOVO NORDIS
      8.1.1 COMPANY OVERVIEW
      8.1.2 FINANCIAL OVERVIEW
      8.1.3 SEGMENT OVERVIEW
      8.1.4 EMPLOYEE STRENGTH
      8.1.5 GEOGRAPHIC OVERVIEW
      8.1.6 GROWTH STRATEGY
      8.1.7 RECENT DEVELOPMENTS
8.2 ELI LILLY AND COMPANY
      8.2.1 COMPANY OVERVIEW
      8.2.2 FINANCIAL OVERVIEW
      8.2.3 SEGMENT OVERVIEW
               8.2.3.1 Neuroscience products
               8.2.3.2 Endocrinology products
               8.2.3.3 Oncology products
               8.2.3.4 Cardiovascular products
      8.2.4 EMPLOYEE STRENGTH
      8.2.5 GEOGRAPHIC SEGMENT
      8.2.6 GROWTH STRATEGY
      8.2.7 RECENT DEVELOPMENTS
8.3 SANOFI-AVENTIS
      8.3.1 KEY PRODUCTS
      8.3.2 BRANDS
      8.3.3 REVENUE CONTRIBUTION BY GEOGRAPHY
      8.3.4 REVENUE TREND
      8.3.5 RECENT DEALS

LIST OF FIGURES

FIG. 1 GLOBAL INSULIN MARKETSIZE, 2011 - 2018 (USD MILLION)
FIG. 2 GLOBAL INSULIN MARKETSIZE VOLUME, 2011 - 2018 (TMU)
FIG. 3 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
FIG. 4 GLOBAL INSULIN MARKET SHARE, 2011
FIG. 5 GLOBAL MODERN INSULIN MARKET SHARE, 2011
FIG. 6 GLOBAL HUMAN INSULIN MARKET SHARE, 2011
FIG. 7 GLOBAL POPULATION GROWTH, 2011 - 2018 (MILLION)
FIG. 8 GLOBAL DIABETES POPULATION GROWTH, 2011 - 2030 (27 – 79 YEARS)
FIG. 9 GLOBAL DIABETES PREVALANCE RATES BY AGE GROUP, 2011 - 2030
FIG. 10 GROSS DOMESTIC PRODUCT PER CAPITA OF GLOBAL, 2011 - 2018 (USD)
FIG. 11 INSULIN MARKET SEGMENTATION
FIG. 12 GLOBAL INSULIN AVERAGE SELLING PRICE AND FORECAST, 2011 - 2018 (USD/TMU)
FIG. 13 GLOBAL INSULIN AVERAGE SELLING PRICE AND FORECAST, BY ACTION 2011 - 2018 (USD/TMU)
FIG. 14 GLOBAL INSULIN AVERAGE SELLING PRICE AND FORECAST, BY ACTION 2011 - 2018 (USD/TMU)
FIG. 15 GLOBAL INSULIN AVERAGE SELLING PRICE AND FORECAST, BY ACTION 2011 - 2018 (USD/TMU)
FIG. 16 CHINESE INSULIN MARKETSIZE, 2011 - 2018 (USD MILLION)
FIG. 17 CHINESE INSULIN MARKETSIZE VOLUME, 2011 - 2018 (TMU)
FIG. 18 CHINESE INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
FIG. 19 CHINA INSULIN MARKET SHARE, 2011 (%)
FIG. 20 POPULATION GROWTH OF CHINA, 2010 - 2018 (MILLION)
FIG. 21 CHINA DIABETES POPULATION GROWTH, 2011 - 2030 (27 – 79 YEARS)
FIG. 22 CHINA DIABETES PREVALANCE RATES BY AGE GROUP, 2011 - 2030
FIG. 23 GROSS DOMESTIC PRODUCT PER CAPITA OF CHINA, 2011 - 2018 (USD)
FIG. 24 CHINA INSULIN AVERAGE SELLING PRICE AND FORECAST, 2011 - 2018 (USD/TMU)
FIG. 25 CHINA INSULIN AVERAGE SELLING PRICE AND FORECAST, BY ACTION 2011 - 2018 (USD/TMU)
FIG. 26 CHINA INSULIN AVERAGE SELLING PRICE AND FORECAST, BY ACTION 2011 - 2018 (USD/TMU)
FIG. 27 CHINA INSULIN AVERAGE SELLING PRICE AND FORECAST, BY ACTION 2011 - 2018 (USD/TMU)
FIG. 28 GLOBAL SHORT ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 29 GLOBAL SHORT ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 30 GLOBAL PRE-MIXES INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 31 GLOBAL PRE-MIXES INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 32 GLOBAL LONG ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 33 GLOBAL LONG ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 34 GLOBAL HUMAN INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 35 GLOBAL HUMAN INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 36 GLOBAL MODERN INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 37 GLOBAL MODERN INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 38 GLOBAL ANIMAL INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 39 GLOBAL ANIMAL INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 40 GLOBAL DOSAGE PURCHASE  INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 41 GLOBAL DOSAGE PURCHASE INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 42 GLOBAL BULK PURCHASE INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 43 GLOBAL BULK PURCHASE  INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 44 CHINA SHORT ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 45 CHINA SHORT ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 46 CHINA PRE-MIXES INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 47 CHINA PRE-MIXESINSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 48 CHINA LONG ACTING INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 49 CHINA LONG ACTING INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 50 CHINA HUMANINSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 51 CHINA HUMANINSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 52 CHINA MODERN INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 53 CHINA MODERNINSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 54 CHINA ANIMAL INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 55 CHINA ANIMAL INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 56 CHINA DOSAGE PURCHASE  INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 57 CHINA DOSAGE PURCHASE INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 58 CHINA BULK PURCHASE INSULIN MARKET REVENUE, 2011 – 2018 (USD MILLION)
FIG. 59 CHINA BULK PURCHASE  INSULIN MARKET VOLUME, 2011 - 2018 (TMU)
FIG. 60 CHINESE INSULIN MARKET SHARE BY KEY PLAYERS, 2009 - 2011
FIG. 61 NOVO NORDISK MARKET SHARE BY CATEGORY IN 2011
FIG. 62 NOVO NORDISK EMPLOYEE STRENGTH 2007-2011
FIG. 63 NOVO NORDISK MARKET SHARE BY GEOGRAPHY, 2011
FIG. 64 ELI-LILLY EMPLOYEE STRENGTH 2007-2011
FIG. 65 ELI-LILLY MARKET SHARE BY GEOGRAPHY,2011
FIG. 66 REVENUE CONTRIBUTION OF SANOFI
FIG. 67 REVENUE TREND OF SANOFI

LIST OF TABLES

TABLE 1 NOVO NORDISK REVENUE GROWTH RATE
TABLE 2 FINANCIAL SUMMARY - NOVO NORDISK. (USD MILLION)
TABLE 3 MARKET SHARE OF NOVO NORDISK BY GEOGRAPHY (2007 - 2011)
TABLE 4 FINANCIAL SUMMARY – ELI-LILLY. (USD MILLION)
TABLE 5 ELI-LILLY SEGMENT REVENUE 2009-2011(IN MILLION)
TABLE 6 ELI-LILLY MARKET SHARE BY GEOGRAPHY (2009-2011)

Enquiry Before Buying




Free Market Analysis




The global market for insulin, supported by rise in diabetic population, is growing at a healthy rate. China, which accounts for the largest share of global diabetic population has become the diabetes capital of the world, and is seen as a high potential market for insulin products. 

Changing lifestyles, dietary habits, increased consumption of fast foods, have triggered a rise in the number of people suffering from diabetes. WHO has forecasted the global diabetic population to rise by more than 50% by year 2030 which will result in a rise in global demand for insulin products. Insulin manufacturers too are continuously developing new products and delivery devices for insulin to sustain and support the growth trend. The increased healthcare spending by individuals and governments all over the world has further boosted the insulin industry growth. 

Insulin is used as a drug for treatment of Diabetes Mellitus Type I and Type II. It comes in three different types – Animal insulin, Human insulin, and Modern insulin. The shortcomings in animal insulin led to the development of human insulin, which gradually took over the entire market of animal insulin. Now, animal insulin is used in trace quantities and rare cases only. But, a similar issue with the absorption capacity of human insulin led to development of modern insulin, also known as insulin analogs. Modern insulin is genetically engineered human insulin, which is modified genetically to induce certain desirable attributes such as quick absorption and action capacity. Currently, the market is dominated by modern insulin, which accounts for the highest revenue share and volume share for the global insulin industry. 

For in-depth and comprehensive analysis of insulin industry, it can be analyzed based on segments classified on the parameters of action time and purchase type. Insulin, irrespective of the origin, based on action, can be segmented as long acting, short acting, and pre-mixes. For purchase type categorization, insulin is segmented into bulk purchase and dosage. A large part of global insulin purchase is done as dosage type only by individuals and health care service providers. 

The high potential and demand for insulin has driven many manufacturers to foray into the segment, which has made the prices competitive and affordable for consumers. Considering the huge market potential for the insulin industry in China, leading manufacturers are focusing on increasing their market presence in China, and have adopted different business strategies. The global manufacturers of insulin, who are leading the China insulin market, are Novo Nordisk, Sanofi-Aventis, and Eli-Lilly who together share more than 90% of the global insulin market.
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research